CTOR Citius Oncology, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 14, 2026
$0.95
· of 52w range
· above low
· to high
$0.4952w low
$2.2552w high
Market Cap (MRQ)
$100M
P/E
-2.8
EPS
$-0.34
your badges
52W Range
$0–$2
Analyst Rating
BUY
Price Target
$4
P/E
-2.8
ROE
-61.5%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
CTOR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.95
Market Cap (MRQ)
$100M
P/E
-2.8
EPS
$-0.34
ROE
-61.5%
52W Range
$0–$2
CTOR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-0.342022-12-31 → 2025-09-30
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CTOR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -2.85Y avg ≈28.7 | ≈28.7 | · | · | |
| P/B (MRQ) | 2.55Y avg ≈20.6 | ≈20.6 | 3.1 | Undervalued | |
| Price / Cash Flow | -14.45Y avg ≈-195.1 | ≈-195.1 | · | · | |
| Price / Tangible Book | 1.85Y avg ≈19.5 | ≈19.5 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CTOR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -26.7%5Y avg ≈-7.2% | ≈-7.2% | -57.6% | Top tier | |
| ROE | -61.5%5Y avg ≈-13.0% | ≈-13.0% | -63.4% | Top tier | |
| ROIC | -54.8% | · | -57.0% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CTOR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 0.75Y avg ≈4.1 | ≈4.1 | 7.7 | Low liquidity | |
| Quick Ratio | 0.15Y avg ≈3.1 | ≈3.1 | 7.5 | Low liquidity | |
| Interest Coverage | -107.9 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CTOR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| EPS YoY | 125.0% | · | · | · | |
| Net Income YoY | 535.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-380.3%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Sept. 30, 2026 | Aug 18, 2026 | $-0.08 | $-0.08 | 2.0% |
| June 30, 2026 | Aug 14, 2026 | $-0.08 | $-0.08 | 2.0% |
| March 31, 2026 | May 15, 2026 | $-0.27 | $-0.01 | -2547.1% |
| Dec. 31, 2025 | $-0.06 | $0.06 | -198.0% | |
| Sept. 30, 2025 | $-0.06 | $-0.12 | 51.0% | |
| June 30, 2025 | $-0.08 | $-0.15 | 47.7% | |
| March 31, 2025 | $-0.11 | $-0.09 | -19.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| R&D Expense | $6M | $5M | · | · | · | |
| SG&A Expense | $9M | $8M | $1M | $138.1K | $10.1K | |
| Operating Expenses | $24M | $21M | · | · | · | |
| Operating Income | $-24M | $-21M | $-1M | $-138.1K | $-10.1K | |
| Interest Expense | $218.0K | · | · | · | · | |
| Interest Income | $36.4K | · | · | · | · | |
| Other Non-op | $-181.7K | · | $3M | $518.9K | · | |
| Pretax Income | $-24M | $-21M | · | · | · | |
| Income Tax | $1M | $576.0K | · | · | · | |
| Net Income | $-25M | $-21M | $2M | $380.8K | $-10.1K | |
| EPS (Basic) | $-0.34 | $-0.31 | $0.27 | $0.12 | $-0.01 | |
| EPS (Diluted) | $-0.34 | $-0.31 | $0.27 | $0.12 | · | |
| Shares (Basic) | 73,267,969 | 68,053,607 | 6,600,000 | 1,341,758 | 1,725,000 | |
| Shares (Diluted) | 73,267,969 | 68,053,607 | 6,600,000 | 1,341,758 | · | |
| EBITDA | $-24M | · | $-1M | $-138.1K | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $112 | $32.7K | $289.2K | · | |
| Inventory | $22M | $8M | · | · | · | |
| Prepaid Expense | $1M | $3M | $25.5K | $88.2K | · | |
| Current Assets | $28M | $11M | $58.2K | $377.3K | $126.4K | |
| Total Assets | $101M | $84M | $73M | $68M | $126.4K | |
| Accounts Payable | $13M | $4M | · | · | · | |
| Accrued Liabilities | $4M | · | $375.9K | · | · | |
| Short-term Debt | · | · | $1M | · | · | |
| Current Liabilities | $49M | $33M | $2M | $31.8K | $136.5K | |
| Deferred Tax | $3M | $2M | · | · | · | |
| Total Liabilities | $56M | $38M | · | · | · | |
| Common Stock | $8.4K | $7.2K | $167 | $242 | $173 | |
| Paid-in Capital | $109M | $85M | · | · | $24.8K | |
| Retained Earnings | $-64M | $-39M | $-2M | $345.3K | $-10.1K | |
| Stockholders' Equity | $45M | $46M | $23M | $345.5K | $-10.1K | |
| Liabilities + Equity | $101M | $84M | $73M | $68M | $126.4K | |
| Shares Outstanding | 83,513,442 | 71,552,402 | 2,341,000 | 2,416,000 | 2,416,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $8M | $7M | · | · | · | |
| Deferred Tax | $1M | $576.0K | · | · | · | |
| Operating Cash Flow | $-5M | $126.4K | $-601.3K | $-48.0K | · | |
| Investing Cash Flow | $-6M | $-5M | $-1M | $-67M | · | |
| Stock Issued | $15M | · | · | $66M | · | |
| Net Stock Activity | $15M | · | · | $66M | · | |
| Financing Cash Flow | $15M | $5M | $2M | $68M | · | |
| Net Change in Cash | · | · | $-256.4K | $289.2K | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| ROA | -26.7% | · | 4.0% | 1.1% | · | |
| ROE | -61.5% | · | 20.5% | 2.1% | · | |
| ROIC | -54.8% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | · | 0.0 | 11.9 | · | |
| Quick Ratio | 0.1 | · | 0.0 | 9.1 | · | |
| Interest Coverage | -107.9 | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Book Value / Share | $0.54 | · | $-0.85 | $0.14 | · | |
| Cash Flow / Share | $-0.07 | · | $-0.09 | $-0.04 | · | |
| Cash / Share | $0.05 | · | $0.01 | $0.12 | · | |
| EPS (TTM) | $-0.34 | $-0.31 | $0.27 | $0.12 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| EPS YoY | · | · | 125.0% | · | · | |
| Net Income YoY | · | · | 535.3% | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-25M | $-21M | $2M | $380.8K | · | |
| Market Cap | $170M | · | $26M | $25M | · | |
| P/E | -6.0 | -4.5 | 40.5 | 84.7 | · | |
| P/B | 3.8 | · | -12.9 | 71.0 | · | |
| P / Tangible Book | 3.8 | 2.2 | 1.1 | 71.0 | · | |
| P / Cash Flow | -30.9 | · | -42.6 | -511.7 | · | |
| Earnings Yield | -16.8% | -22.3% | 2.5% | 1.2% | · |
Income Statement
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Revenue | $1M | $2M | $4M | |
| Cost of Revenue | $491.8K | $328.9K | $789.2K | |
| Gross Profit | $1M | $1M | $3M | |
| R&D Expense | $218.5K | $1M | $1M | |
| SG&A Expense | $4M | $24M | $3M | |
| Operating Expenses | $10M | $30M | $8M | |
| Operating Income | $-9M | $-29M | $-5M | |
| Interest Income | $96.8K | $43.7K | $28.3K | |
| Other Non-op | $-314.4K | $2M | $-17.6K | |
| Pretax Income | $-9M | $-27M | $-5M | |
| Income Tax | $-107.3K | $-231.2K | $264.2K | |
| Net Income | $-9M | $-27M | $-6M | |
| EPS (Basic) | $-0.08 | $-0.27 | $-0.06 | |
| EPS (Diluted) | $-0.08 | $-0.27 | $-0.06 | |
| Shares (Basic) | 107,890,452 | 100,027,204 | 87,462,385 | |
| Shares (Diluted) | 107,890,452 | 100,027,204 | 87,462,385 | |
| EBITDA | $-9M | $-29M | $-5M |
Balance Sheet
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Cash & Equivalents | $17M | $3M | $7M | |
| Receivables | $686.2K | $1M | $4M | |
| Inventory | $23M | $23M | $23M | |
| Prepaid Expense | $3M | $3M | $3M | |
| Current Assets | $43M | $29M | $37M | |
| Total Assets | $112M | $101M | $110M | |
| Accounts Payable | $7M | $9M | $10M | |
| Accrued Liabilities | $26M | $24M | $5M | |
| Current Liabilities | $59M | $59M | $45M | |
| Deferred Tax | $3M | $3M | $3M | |
| Total Liabilities | $72M | $65M | $52M | |
| Common Stock | $10.6K | $9.3K | $8.5K | |
| Paid-in Capital | $145M | $131M | $128M | |
| Retained Earnings | $-105M | $-96M | $-70M | |
| Stockholders' Equity | $40M | $35M | $58M | |
| Liabilities + Equity | $112M | $101M | $110M | |
| Shares Outstanding | 105,758,982 | 92,981,204 | 84,797,846 |
Cash Flow
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Stock-based Comp | $4M | $4M | $4M | |
| Deferred Tax | $-107.3K | $-231.2K | $264.2K | |
| Operating Cash Flow | $-3M | $-4M | $-7M | |
| Investing Cash Flow | $-2M | $-600.0K | $-4M | |
| Stock Issued | $-818 | $-61.9K | $15M | |
| Net Stock Activity | · | · | $15M | |
| Financing Cash Flow | $19M | $-231.2K | $15M |
Profitability
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Gross Margin | 67.1% | 80.3% | 80.0% | |
| Operating Margin | -583.5% | -1716.2% | -133.2% | |
| Net Margin | -597.4% | -1596.0% | -140.3% | |
| Pretax Margin | -604.6% | -1609.8% | -133.6% | |
| EBITDA Margin | -583.5% | -1716.2% | -133.2% | |
| ROA | -8.8% | -27.7% | -5.5% | |
| ROE | -24.5% | -75.0% | -11.1% | |
| ROIC | -21.3% | -80.4% | -9.4% |
Liquidity & Solvency
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Current Ratio | 0.7 | 0.5 | 0.8 | |
| Quick Ratio | 0.3 | 0.1 | 0.3 |
Efficiency
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 4.4 | 3.1 | 1.9 |
Per Share
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Book Value / Share | $0.38 | $0.38 | $0.69 | |
| Revenue / Share | $0.01 | $0.02 | $0.05 | |
| Cash Flow / Share | · | · | $-0.08 | |
| Cash / Share | $0.16 | $0.03 | $0.09 | |
| EPS (TTM) | $-0.47 | $-0.47 | $-0.31 |
Valuation (TTM)
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Net Income TTM | $-46M | $-43M | $-24M | |
| Market Cap | $69M | $58M | $85M | |
| P/E | -1.4 | -1.3 | -3.2 | |
| P/B | 1.7 | 1.6 | 1.5 | |
| P / Tangible Book | 1.7 | 1.6 | 1.5 | |
| P / Cash Flow | · | · | -11.5 | |
| Earnings Yield | -72.3% | -75.8% | -31.0% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-09-30 | 2024-09-30 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Net Income | $-25M | $-21M | $2M | $-13M | $380.8K |
| Diluted EPS | $-0.34 | $-0.31 | $0.27 | $-0.19 | $0.12 |
| Metric | 2025-09-30 | 2024-09-30 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 0.6 | · | 0.0 | · | 11.9 |
| Quick Ratio | 0.1 | · | 0.0 | · | 9.1 |
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 20 filers · $9.8M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
20
Value held
$9.8M
New positions
7
Exited positions
2
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+4 vs prior Q) | 2 (-3 vs prior Q) | 2 (-5 vs prior Q) | 3 (+2 vs prior Q) | -103K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $5,659,503 | 8,705,589 | 57.88% | Shares |
| BANK OF AMERICA CORP /DE/ | $2,492,854 | 3,835,160 | 25.49% | Shares |
| VANGUARD GROUP INC | $596,997 | 596,997 | 6.11% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $355,111 | 546,325 | 3.63% | Shares |
| UBS Group AG | $217,502 | 334,619 | 2.22% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $159,538 | 245,407 | 1.63% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $79,242 | 121,910 | 0.81% | Shares |
| IFP Advisors, Inc | $69,836 | 107,424 | 0.71% | Shares |
| CITADEL ADVISORS LLC | $58,890 | 90,586 | 0.60% | Shares |
| NORTHERN TRUST CORP | $29,739 | 45,746 | 0.30% | Shares |
| STATE STREET CORP | $27,889 | 42,900 | 0.29% | Shares |
| XTX Topco Ltd | $13,417 | 20,638 | 0.14% | Shares |
| Tower Research Capital LLC (TRC) | $8,982 | 13,816 | 0.09% | Shares |
| Arkadios Wealth Advisors | $7,584 | 11,666 | 0.08% | Shares |
| OSAIC HOLDINGS, INC. | $650 | 1,000 | 0.01% | Shares |
| WELLS FARGO & COMPANY/MN | $325 | 500 | 0.00% | Shares |
| BARCLAYS PLC | $59 | 90 | 0.00% | Shares |
| MORGAN STANLEY | $15 | 23 | 0.00% | Shares |
| Virtu Financial LLC | $14 | 21,877 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $1 | 1 | 0.00% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. ×4 filings | June 4, 2026 | 71.00% | Amendment | · | SEC |
| Citius Pharmaceuticals, Inc. (2) | Aug. 16, 2024 | · | Initial filing | M&A / sale | SEC |
| 10XYZ Holdings LP ×2 filings | Aug. 15, 2024 | · | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 10 insiders · 4 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Leonard L Mazur | Chief Executive Officer | Sept. 19, 2025 A | 1,700,000 | 0 | 0 | $0 |
| Jaime Bartushak | Chief Financial Officer | Sept. 19, 2025 A | 825,000 | 0 | 0 | $0 |
| Myron Czuczman | Chief Medical Officer | Sept. 19, 2025 A | 825,000 | 0 | 0 | $0 |
| Myron Z Holubiak | Secretary | Sept. 19, 2025 A | 850,000 | 0 | 0 | $0 |
| Robert Joseph Smith | Director | Sept. 19, 2025 A | 300,000 | 0 | 0 | $0 |
| Eugene Myron Holuka | Director | Sept. 19, 2025 A | 300,000 | 0 | 0 | $0 |
| Carol Webb | Director | Sept. 19, 2025 A | 300,000 | 0 | 0 | $0 |
| Joel David Mayersohn | Director | Sept. 19, 2025 A | 321,228 | 0 | 0 | $0 |
| Suren G Dutia | Director | Sept. 19, 2025 A | 300,000 | 0 | 0 | $0 |
| Dennis M Mcgrath | Director | Sept. 19, 2025 A | 300,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
CTOR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 7 analysts
BUY
Median target
$4.00
+321.1%
2 28.6%
Strong Buy
4 57.1%
Buy
1 14.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
1 analysts · 2026-09-28Mean target $4.00 +321.1%
Low$4.00
Mean$4.00
High$4.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CTOR | $170M | -6.0 | · | · | -61.5% | · |
| OKUR | · | -0.7 | · | -1733.7% | -88.6% | · |
| ANIX | $136M | -12.1 | 0.00% | · | -62.2% | · |
| BMEA | $90M | -1.1 | -67.1% | -3326.0% | -216.6% | · |
| CNXU | · | · | · | · | · | · |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | · |
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | · |
| EQ | $95M | -4.0 | 13.9% | · | -133.1% | · |
| CRDF | $192M | -4.1 | -13.2% | -7732.0% | -88.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 14, 2026